Filing Details

Accession Number:
0001209191-23-059266
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-12-19 19:42:03
Reporting Period:
2023-12-15
Accepted Time:
2023-12-19 19:42:03
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1796280 Oric Pharmaceuticals Inc. ORIC () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1586894 S Pratik Multani C/O Oric Pharmaceuticals, Inc.
240 E. Grand Ave., 2Nd Floor
South San Francisco CA 94080
Chief Medical Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2023-12-15 14,042 $0.00 29,091 No 4 M Direct
Common Stock Disposition 2023-12-15 5,282 $8.59 23,809 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Restricted Stock Unit Disposition 2023-12-15 6,042 $0.00 6,042 $0.00
Common Stock Restricted Stock Unit Disposition 2023-12-15 8,000 $0.00 8,000 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
6,042 No 4 M Direct
16,000 No 4 M Direct
Footnotes
  1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. (the "Issuer") Common Stock.
  2. Includes an aggregate of 7,764 shares of Common Stock acquired under the Issuer's 2020 Employee Stock Purchase Plan.
  3. Represents the number of shares sold to cover the tax withholding obligations in connection with the vesting of RSUs and does not represent a discretionary sale by the Reporting Person.
  4. Represents the weighted average share price of an aggregate total of 5,282 shares sold in the price range of $8.57 to $8.795 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
  5. 1/3 of the RSUs subject to the award shall vest on each of December 15, 2022, December 15, 2023 and December 15, 2024.
  6. 1/3 of the RSUs subject to the award shall vest on each of December 15, 2023, December 15, 2024 and December 15, 2025.